3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Colorectal Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
12
pembrolizumab
9
Oxaliplatin
9
Nivolumab
9
Leucovorin
8
Capecitabine
7
Cisplatin
6
Trastuzumab
4
Paclitaxel
3
Drug Therapy
3
Docetaxel
3
zimberelimab
2
zanidatamab
2
tucatinib
2
spartalizumab
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
zolbetuximab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tezacitabine
1
ribociclib
1
quemliclustat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma Of Esophagus
×
quemliclustat
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled